Stockwatch: Reheating the burnt offering
This article was originally published in Scrip
Executive Summary
As the board of the Chinese biotechnology company 3SBio considers the offer from a local consortium that includes their chairman and CEO to take the company back into private ownership (scripintelligence.com, 14 September 2012), shareholders may well appreciate a retrospective on how well take-private transactions have fared at other biotechnology companies.